A novel ultrasensitive assay for plasma p-tau217: performance in individuals with subjective cognitive decline and early Alzheimer's disease.
Fernando González-OrtizPamela C L FerreiraArmand GonzalezLaia Montoliu-GayaPaula Ortiz-RomeroPrzemyslaw R KacMichael TurtonHlin KvartsbergNicholas J AshtonHenrik ZetterbergPeter HarrisonBruna BellaverGuilherme PovalaVictor L VillemagneTharick A PascoalMary GanguliAnne D CohenCarolina MiguillonJose ContadorMarc Suarez-CalvetJonathan M SchottKaj BlennowPublished in: medRxiv : the preprint server for health sciences (2023)
UGOT p-tau217 can be an easily accessible and efficient way to screen and monitor patients with suspected AD pathophysiology, even in the early stages of the continuum.